| Ahmer Younas, MD | |
|
844 N 5th Ave, Sequim, WA 98382-3045 | |
| (360) 683-9895 | |
| (360) 582-5614 |
| Full Name | Ahmer Younas |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Medical Oncology |
| Location | 844 N 5th Ave, Sequim, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396754289 | NPI | - | NPPES |
| 185636101 | Medicaid | TX | |
| P00964044 | Other | TX | RAILROAD MEDICARE |
| 185636102 | Medicaid | TX | |
| 185636106 | Medicaid | TX | |
| 185636107 | Medicaid | TX | |
| 140819704 | Medicaid | TX |
| Entity Name | Texas Oncology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811944101 PECOS PAC ID: 5395658934 Enrollment ID: O20031124000323 |
News Archive
Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.
An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.
XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.
After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ahmer Younas, MD Po Box 850, Port Angeles, WA 98362-0146 Ph: (360) 683-9895 | Ahmer Younas, MD 844 N 5th Ave, Sequim, WA 98382-3045 Ph: (360) 683-9895 |
News Archive
Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.
An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.
XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.
After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.
› Verified 9 days ago
Dr. Carl G Weber, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 800 N 5th Ave, Ste 101, Sequim, WA 98382 Phone: 360-582-2690 Fax: 360-582-2691 | |
Samantha F Reiter, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 840 N 5th Ave, Ste 100, Sequim, WA 98382 Phone: 360-582-2850 Fax: 360-582-2851 | |
Dr. Eiko Klimant, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 844 N 5th Ave, Sequim, WA 98382 Phone: 360-683-9895 Fax: 360-582-5614 | |
Carrie L Sun, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 N 5th Ave, Sequim, WA 98382 Phone: 360-565-0999 Fax: 360-582-4221 | |
Dr. David Patrick Murphy, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 840 N 5th Ave Ste 1500, Sequim, WA 98382 Phone: 360-565-0999 Fax: 360-582-2841 | |
Dr. Frank Henry Jahns, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 840 N 5th Ave Ste 1500, Sequim, WA 98382 Phone: 360-565-0999 Fax: 360-582-2841 | |
Harry Everett Lyndes, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 777 N 5th Ave, Suite 105, Sequim, WA 98382 Phone: 360-582-2623 Fax: 360-582-9623 |